Advertisement

Potential Therapeutic Strategies for Neurodegenerative Diseases

  • Akhlaq A. Farooqui
Chapter

Abstract

Neurodegenerative diseases include Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD), amyotrophic lateral sclerosis (ALS), and prion diseases. The primary causes of neurodegenerative diseases are not known.

Keywords

Amyotrophic Lateral Sclerosis Alzheimer Disease Parkinson Disease Amyloid Precursor Protein Amyotrophic Lateral Sclerosis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618PubMedCrossRefGoogle Scholar
  2. Adlerz L, Holback S, Multhaup G, Iverfeldt K (2009) IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 282:10203–10209CrossRefGoogle Scholar
  3. Aguzzi A, Baumann F, Bremer J (2008) The prion’s elusive reason for being. Ann Rev Neurosci 31:439–477PubMedCrossRefGoogle Scholar
  4. Alexandrenne C, Hanoux V, Dkhissi F, Boquet D, Couraud JY, Wijkhuisen A (2009) Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies. J Neuroimmunol 209:50–56PubMedCrossRefGoogle Scholar
  5. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis 8:479–491PubMedCrossRefGoogle Scholar
  6. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB (2007) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4:403–411PubMedCrossRefGoogle Scholar
  7. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer’s disease. Curr Med Chem 14:2848–2864PubMedCrossRefGoogle Scholar
  8. Bartke A, Bonkowski M, Masternak M (2008) Thow diet interacts with longevity genes. Hormones 7:17–23PubMedGoogle Scholar
  9. Bate C, Tayebi M, Diomede L, Salmona M, Williams A (2009) Glimepiride reduces the expression of PrP, prevents PrP formation and protects against prion mediated neurotoxicity in cell lines. PLoS One 4(12):e8221PubMedCrossRefGoogle Scholar
  10. Bauer PO, Wong HK, Oyama F, Goswami A, Okuno M, Kino Y, Miyazaki H, Nukina N (2009) Inhibition of rho kinases enhances the degradation of mutant huntingtin. J Biol Chem 284:13153–13164PubMedCrossRefGoogle Scholar
  11. Bazan NG (2005) Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15:159–166PubMedCrossRefGoogle Scholar
  12. Bazan NG (2006) The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol 26:901–913PubMedCrossRefGoogle Scholar
  13. Bazan NG (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 10:136–141PubMedCrossRefGoogle Scholar
  14. Beal MF (2009) Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S189–S194PubMedCrossRefGoogle Scholar
  15. Benoit E, Escande D (1991) Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 419:603–609PubMedCrossRefGoogle Scholar
  16. Benesimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosisALS/Riluzole Study Group. N Engl J Med 330:585–591CrossRefGoogle Scholar
  17. Bilsland LG, Greensmith L (2008) The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 14:2306–2316PubMedCrossRefGoogle Scholar
  18. Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev (1):CD005593Google Scholar
  19. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington’s disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19:337–342PubMedCrossRefGoogle Scholar
  20. Bonini NM, La Spada AR (2005) Silencing polyglutamine degeneration with RNAi. Neuron 48:715–718PubMedCrossRefGoogle Scholar
  21. Bousquet M, Saint-Pierre M, Julien C, Salem N Jr., Cicchetti F, Calon F (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. FASEB J 22:1213–1225PubMedCrossRefGoogle Scholar
  22. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82:615–624PubMedCrossRefGoogle Scholar
  23. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344PubMedCrossRefGoogle Scholar
  24. Bueler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp Neurol 218:235–246PubMedCrossRefGoogle Scholar
  25. Buisson B, Bertrand D (1998) Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555–563PubMedGoogle Scholar
  26. Calon F, Lim GP, Yang FS, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem NJ, Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 43:633–645PubMedCrossRefGoogle Scholar
  27. Calon F, Cole G (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prost Leukot Essent Fatty Acids 77:287–293CrossRefGoogle Scholar
  28. Carro E, Trejo JL, Busiguina S, Torres-Aleman I (2001) Circulating insulin-like growth factor I mediates the protective effects of physical exercise. J Neurosci 21:5678–5684PubMedGoogle Scholar
  29. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s disease. Eur J Pharmacol 490:127–133PubMedCrossRefGoogle Scholar
  30. Chaturvedi RK, Beal MF (2008) PPAR: a therapeutic target in Parkinson’s disease. J Neurochem 106:506–518PubMedCrossRefGoogle Scholar
  31. Chauhan NB, Siegel GJ (2004) Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer’s disease. Expert Rev Vaccines 3:717–725PubMedCrossRefGoogle Scholar
  32. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797–801PubMedCrossRefGoogle Scholar
  33. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal anti-inflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58:963–967PubMedCrossRefGoogle Scholar
  34. Chen MJ, Russo-Neustdt AA (2007) Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. Growth Factor 25:118–131CrossRefGoogle Scholar
  35. Chen JX, Yan SD (2007a) Amyloid-beta-induced mitochondrial dysfunction. J Alzheimer Dis 12:177–184Google Scholar
  36. Chen JX, Yan SD (2007b) Pathogenic role of mitochondrial [correction of mitochondrial] amyloid-beta peptide. Expert Rev Neurother 7:1517–1525PubMedCrossRefGoogle Scholar
  37. Chen Y, Meiminger V, Guillemin GJ (2009) Recent advances in the treatment of amyotrophic lateral sclerosis emphasis on kynurenine pathway inhibitors. Cent Nerv Syst Agents Med Chem 9:32–39PubMedCrossRefGoogle Scholar
  38. Chéramy A, Barbeito L, Godeheu G, Glowinski J (1992) Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209–212PubMedCrossRefGoogle Scholar
  39. Cole GM, Ma QL, Frautschy SA (2009) Omega-3 fatty acids and dementia. Prost Leukot Essent Fatty Acids 81:213–221CrossRefGoogle Scholar
  40. Coppede F, Mancuso M, Siciliano G, Migliore L, Murri L (2006) Genes and the environment in neurodegeneration. Biosci Rep 26:341–367PubMedCrossRefGoogle Scholar
  41. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr., Rimmler JB, Locke PA, Conneally PM, Schmader KE (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180–184PubMedCrossRefGoogle Scholar
  42. Cordle A, Landreth G (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J Neurosci 25:299–307PubMedCrossRefGoogle Scholar
  43. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280:34202–34209PubMedCrossRefGoogle Scholar
  44. Cotman CW (2005) The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 30:877–881PubMedCrossRefGoogle Scholar
  45. Das VN, Vaddadi KS (2004) Essential fatty acids in Huntington’s disease. Nutrition 20:942–947PubMedCrossRefGoogle Scholar
  46. Dealler S, Rainov NG (2003) Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. IDrugs 6:470–478PubMedGoogle Scholar
  47. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494–501PubMedCrossRefGoogle Scholar
  48. Delattre AM, Kiss A, Szawka RE, Anselmo-Franci JA, Bagatini PB, Xavier LL, Rigon P, Achaval M, Iagher F, de David C, Marroni NA, Ferraz AC (2009) Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson’s disease. Neurosci Res 24 Nov 2009 [Epub ahead of print]Google Scholar
  49. de Oliveria DM, Barreto G, De Anrade DV, Dos El Bacha R, Goraldez LD (2009) Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease. Neurochem Res 34:215–220PubMedCrossRefGoogle Scholar
  50. Ding O, Vaynman S, Akhavan M, Ying Z, Gomez-Pinilla F (2006) Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 140:823–833PubMedCrossRefGoogle Scholar
  51. Doble A, Hubert JP, Blanchard JC (1992) Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 140:251–254PubMedCrossRefGoogle Scholar
  52. Doh-ura K (2004) Prion diseases: disease diversity and therapeutics. Rinsho Shinkeigaku 44:855–856PubMedGoogle Scholar
  53. Doh-ura K (2009) Innovation of therapeutics and prophylaxis for prion diseases. Rinsho Shinkeigaku 49:946–948PubMedCrossRefGoogle Scholar
  54. Eibl JK, Chapelsky SA, Ross GM (2010) Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J Pharmacol Exp Ther 332:446–454PubMedCrossRefGoogle Scholar
  55. Endres M (2005) Statins and stroke. J Cereb Blood Flow Metab 25:1093–1110PubMedCrossRefGoogle Scholar
  56. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 205:295–312PubMedCrossRefGoogle Scholar
  57. Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284:14–30PubMedCrossRefGoogle Scholar
  58. Farooqui AA, Horrocks LA (2007) Glycerophospholipids in the brain: phospholipases A2 in neurological disorders. Springer, New York, NY, pp 1–394Google Scholar
  59. Farooqui AA, Horrocks LA, Farooqui T (2007a) Modulation of inflammation in brain: a matter of fat. J Neurochem 101:577–599PubMedCrossRefGoogle Scholar
  60. Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T (2007b) Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Rev 56:443–471PubMedCrossRefGoogle Scholar
  61. Farooqui AA (2009a) Hot topics in neural membrane lipidology. Springer, New York, NYCrossRefGoogle Scholar
  62. Farooqui AA (2009b) Beneficial effects of fish oil on human brain. Springer, New York, NYCrossRefGoogle Scholar
  63. Farooqui T, Farooqui AA (2009) Aging: an important factor for the pathogenesis of neurodegenerative diseases. Mech Ageing Dev 130:203–215PubMedCrossRefGoogle Scholar
  64. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci 20:4389–4397PubMedGoogle Scholar
  65. Farrelly PV, Kenna BL, Laohachai KL, Bahadi R, Salmona M, Forloni G, Kourie JI (2003) Quinacrine blocks PrP (106–126)-formed channels. J Neurosci Res 74:934–941PubMedCrossRefGoogle Scholar
  66. Fisher A (2007) M1 muscarinic agonists target major hallmarks of Alzheimer’s disease – an update. Curr Alzheimer Dis 4:577–580CrossRefGoogle Scholar
  67. Follette P (2003) New perspectives for prion therapeutics meeting Prion disease treatment’s early promise unravels. Science 299:191–192PubMedCrossRefGoogle Scholar
  68. Fontan-Lozano A, Lopez-lluch G, Delgado-Garcia JM, Navas P, Carrion AM (2008) Molecular bases of caloric restriction regulation of neuronal synaptic plasticity. Mol Neurobiol 38:167–177PubMedCrossRefGoogle Scholar
  69. Fratiglioni L, Qiu C (2009) Prevention of common neurodegenerative disorders in the elderly. Exp Gerontol 44:46–50PubMedCrossRefGoogle Scholar
  70. Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C, Udelhoven M, Leeser U, Muller M, Kubota N, Kadowaki T, Krone W, Schroder H, Bruning JC, Schubert M (2009a) Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer’s disease. FASEB J 23:3315–3324PubMedCrossRefGoogle Scholar
  71. Freude S, Schilbach K, Schubert M (2009b) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer’s disease: from model organisms to human disease. Curr Alzheimer Res 6:213–223PubMedCrossRefGoogle Scholar
  72. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63:1402–1408PubMedCrossRefGoogle Scholar
  73. Frisardi V, Solfrizzi V, Imbimbo BP, Capurso C, D‘Introno A, Colacicco AM, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F (2009) Towards disease-modifying treatment of alzheimer’s disease: drugs targeting beta-amyloid. Curr Alzheimer Res 26 Nov 2009 [Epub ahead of print]Google Scholar
  74. Fuenzalida K, Quintanila R, Ramos P, Pident D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M (2007) Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282:37006–37015PubMedCrossRefGoogle Scholar
  75. Ghosh A, Kumaragurubaran N, Tang J (2005) Recent developments of structure-based β-secretase inhibitor’s for Alzheimer’s disease. Curr Top Med Chem 5:1609–1622PubMedCrossRefGoogle Scholar
  76. Ghosh S, Novak EM, Innis SM (2007) Cardiac proinflammatory pathways are altered with different dietary n-6 linoleic to n-3 α-linolenic acid ratios in normal, fat-fed pigs. Am J Physiol Heart Circ Physiol 293:H2919–H2927PubMedCrossRefGoogle Scholar
  77. Ghosh A, Roy A, Matras J, Brahmchari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurosci 29:13543–13556PubMedCrossRefGoogle Scholar
  78. Gilgun-Sherki Y, Melamed E, Offen D (2006) Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharmaceut Des 12:3509–3519CrossRefGoogle Scholar
  79. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L (2005) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353–368PubMedCrossRefGoogle Scholar
  80. Gozes I (2007) Activity-dependent neuroprotective protein: from gene to drug candidate. Pharm Therp 114:146–154CrossRefGoogle Scholar
  81. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D (2009) Addressing Alzheimer’s disease tangles: from NAP to AL-108. Curr Alzheimer Res 6:455–460PubMedCrossRefGoogle Scholar
  82. Graeber MB, Moran LB (2002) Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol 12:385–390PubMedCrossRefGoogle Scholar
  83. Greulich W, Fenger E (1995) J Neural Transm 46(Suppl):415–421Google Scholar
  84. Joseph JA, Shukitt-Hale B, Lau FC (2007) Fruit polyphenols and their effects on neuronal signaling and behavior in senescence. Ann NY Acad Sci 1100:470–485PubMedCrossRefGoogle Scholar
  85. Guentchev M, Voigtlander T, Haberler C, Groschup MH, Budka H (2000) Evidence for oxidative stress in experimental prion disease. Neurobiol Dis 7:270–273PubMedCrossRefGoogle Scholar
  86. Hashimoto M, Hossain S, Agdul H, Shido O (2005) Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 1738:91–98PubMedCrossRefGoogle Scholar
  87. Hashimoto M, Hossain S, Shimada T, Shido O (2006) Docosahexaenoic acid-induced protective effect against impaired learning in amyloid β-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 33:934–939PubMedCrossRefGoogle Scholar
  88. Hashimoto M, Shahdat HM, Yamashita S, Katakura M, Tanabe Y, Fujiwara H, Gamoh S, Miyazawa T, Arai H, Shimada T, Shido O (2008) Docosahexaenoic acid disrupts in vitro amyloid beta fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer’s disease model rats. J Neurochem 107:1634–1646PubMedCrossRefGoogle Scholar
  89. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031–1045PubMedCrossRefGoogle Scholar
  90. Heneka MT, Landreth GE, Hull M (2007) Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 3:496–504PubMedCrossRefGoogle Scholar
  91. Heppner FL, Aguzzi A (2004) Recent developments in prion immunotherapy. Curr Opin Immunol 16:594–598PubMedCrossRefGoogle Scholar
  92. Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT (2009) Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson’s disease. Neurosurgery 64:602–612PubMedCrossRefGoogle Scholar
  93. Hirohata M, Ono K, Yamada M (2008) Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 14:3280–3294PubMedCrossRefGoogle Scholar
  94. Hong M, Mukhida K, Mendez I (2008) GDNF therapy for Parkinson’s disease. Expert Rev Neurother 8:1125–1139PubMedCrossRefGoogle Scholar
  95. Hooper NM, Turner AJ (2002) The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer’s disease. Curr Med Chem 9:1107–1119PubMedCrossRefGoogle Scholar
  96. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125PubMedCrossRefGoogle Scholar
  97. Howe CL, Vergstrom RA, Horazdovsky BF (2009) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 73:1247PubMedCrossRefGoogle Scholar
  98. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp2) as β-secretase. Mol Cell Neurosci 14:419–427PubMedCrossRefGoogle Scholar
  99. Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y, Okuyama H (2000) Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci Lett 285:99–102PubMedCrossRefGoogle Scholar
  100. Jacobsen KT, Adlerz L, Multhaup G, Iverfeldt K (2010) Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-{beta} precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J Biol Chem 5 Feb 2010 [Epub ahead of print]Google Scholar
  101. Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 21:677–692PubMedCrossRefGoogle Scholar
  102. Jeng BH, Galor A, Lee MS, Meisler DM, Hellyfield JG (2008) Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Opthalmology 115:1540–1544CrossRefGoogle Scholar
  103. Ji Y, Pang PT, Feng L, Lu B (2005) Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 8:164–172PubMedCrossRefGoogle Scholar
  104. Jiang Q, Heneka M, Landreth GE (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs 22:1–14PubMedCrossRefGoogle Scholar
  105. Jin H, Randazzo J, Zhang P, Kador PF (2010) Multifunctional antioxidants for the treatment of age-related diseases. J Med Chem 53:1117–1127PubMedCrossRefGoogle Scholar
  106. Kalinin S, Richardson JC, Feinstein DL (2009) A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res 6:431–437PubMedCrossRefGoogle Scholar
  107. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42:776–782PubMedCrossRefGoogle Scholar
  108. Kaufer D, Gandy S (2009) APOE {epsilon}4 and bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73:2052–2053PubMedCrossRefGoogle Scholar
  109. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, et al (2009) Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 66:235–244PubMedCrossRefGoogle Scholar
  110. Kidd PM (2005) Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev 10:268–293PubMedGoogle Scholar
  111. Kobayashi Y, Hirata K, Tanaka H, Yamada T (2003) Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft – an EEG evaluation. Rinsho Shinkeigaku 43:403–408PubMedGoogle Scholar
  112. Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, Soda K (2006) Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 349:1139–1144PubMedCrossRefGoogle Scholar
  113. Kojro E, Fahrenholz F (2005) The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem 38:105–127PubMedCrossRefGoogle Scholar
  114. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 221:267–274PubMedCrossRefGoogle Scholar
  115. Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98:9836–9841PubMedCrossRefGoogle Scholar
  116. Kummer MP, Heneka MT (2008) PPARs in Alzheimer’s disease. PPAR Res 2008Google Scholar
  117. Lacomblez L, Bensiman G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425–1431PubMedGoogle Scholar
  118. Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH (2007) How and when environmental agents and dietary factors affect the course of Alzheimer’s disease: the “LEARn” model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4:219–228PubMedCrossRefGoogle Scholar
  119. Lai A, Frishman WH (2005) Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 13:285–292PubMedCrossRefGoogle Scholar
  120. Landreth G, Jiang Q, Mandrekar S, Henecka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5:481–489PubMedCrossRefGoogle Scholar
  121. Lau FC, Shukitt-Hale B, Joseph JA (2007) Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell Biochem 42:299–318PubMedCrossRefGoogle Scholar
  122. Lee J, Duan W, Long JM, Ingram DK, Mattson MP (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 15:99–108PubMedCrossRefGoogle Scholar
  123. Lemere CA, Mair M, Peng Y, Jiang L, Seabrook T (2007) Novel Abeta immunogens: is shorter better? Curr Alzheimer Res 4:427–436PubMedCrossRefGoogle Scholar
  124. Lemere CA (2009) Developing novel immunogens for a safe and effective Alzheimer’s disease vaccine. Prog Brain Res 175:83–93PubMedCrossRefGoogle Scholar
  125. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A (2009) Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 24:1217–1221PubMedCrossRefGoogle Scholar
  126. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto L, Levin B, Thompson JL (2006) A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 66:660–663PubMedCrossRefGoogle Scholar
  127. Li L, Tang BL (2005) Environmental enrichment and neurodegenerative diseases. Biochem Biophys Res Commun 334:293–297PubMedCrossRefGoogle Scholar
  128. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25:3032–3040PubMedCrossRefGoogle Scholar
  129. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci USA 97:1456–1460PubMedCrossRefGoogle Scholar
  130. Lindvall O, Wahlberg LU (2008) Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson’s disease? Exp Neurol 209:82–88PubMedCrossRefGoogle Scholar
  131. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA (2002) Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation. Trends Neurosci 25:474–480PubMedCrossRefGoogle Scholar
  132. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160–170PubMedCrossRefGoogle Scholar
  133. Long J, Gao H, Sun L, Liu J, Zhao-Wilson X (2009) Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res 12:321–331PubMedCrossRefGoogle Scholar
  134. Lopez-Miranda J, Delgado-Lista J, Perez-Martinez P, Jimenez-Gómez Y, Fuentes F, Ruano J, Marin C (2007) Olive oil and the haemostatic system. Mol Nutr Food Res 51:1249–1259PubMedGoogle Scholar
  135. Love R (2001) Ethnic labels may not predict individuals’ responses to drugs. Lancet 358(9292):1519PubMedCrossRefGoogle Scholar
  136. Lu B (2003) BDNF and activity-dependent synaptic modulation. Learn Mem 10:86–98PubMedCrossRefGoogle Scholar
  137. Luchsinger JA, Noble JM, Scarmeas N (2007) Diet and Alzheimer’s disease. Curr Neurol Neurosci Rep 7:366–372PubMedCrossRefGoogle Scholar
  138. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115:2774–2783PubMedCrossRefGoogle Scholar
  139. Lukiw WJ, Zhao Y, Cui JG (2008) An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283:31315–31322PubMedCrossRefGoogle Scholar
  140. Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H, Liao FF (2009a) Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J Neurosci 29:11226–11236PubMedCrossRefGoogle Scholar
  141. Ma QL, Yang F, Rosario ER, Ubeda QJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautchy SA, Cole GM (2009b) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29:9078–9089PubMedCrossRefGoogle Scholar
  142. Mancuso M, orsucci D, Volpi L, Calsolaro V, Siciliano G (2010) Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 11:111–121PubMedCrossRefGoogle Scholar
  143. Mans RA, Chowdhury N, Cao D, McMahon LL, Li L (2010) Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 166:435–444PubMedCrossRefGoogle Scholar
  144. Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, Chang Q (2009) The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp Neurol 218:333–346PubMedCrossRefGoogle Scholar
  145. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E (2001) The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 18:247–258PubMedCrossRefGoogle Scholar
  146. Mattson MP (2008) Awareness of hormesis will enhance future research in basic and applied neuroscience. Crit Rev Toxicol 38:633–639PubMedCrossRefGoogle Scholar
  147. May BCH, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, Cohen FE (2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 100:3416–3421PubMedCrossRefGoogle Scholar
  148. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 2:CD003160PubMedGoogle Scholar
  149. Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B (2005) Exacerbation of Lewy bodies dementia due to memantine. J Alzheimer Dis 8:289–291Google Scholar
  150. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA (2004) Axonal neuregulin-1 regulates myelin sheath thickness. Science 304:700–703PubMedCrossRefGoogle Scholar
  151. Milhavet O, McMahon HE, Rachidi W, Nishida N, Katamine S, Mange A, Arlotto M, Casanova D, Riondel J, Favier A, Lehmann S (2000) Prion infection impairs the cellular response to oxidative stress. Proc Natl Acad Sci USA 97:13937–13942PubMedCrossRefGoogle Scholar
  152. Minguez-Castellanos A, Escamilla-Sevilla F (2005) Cell therapy and other neuroregenerative strategies in Parkinson’s disease (I). Rev Neurol 41:604–614PubMedGoogle Scholar
  153. Mochizuki H (2009) Current status of gene therapy for Parkinson disease. Brain Nerve 61:485–493PubMedGoogle Scholar
  154. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60:940–946PubMedCrossRefGoogle Scholar
  155. Muller-Schiffmann A, Korth C (2008) Vaccine approaches to prevent and treat prion infection: progress and challenges. BioDrugs 22:45–52PubMedCrossRefGoogle Scholar
  156. Munoz-Torrero D (2008) Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr Med Chem 15:2433–2455PubMedCrossRefGoogle Scholar
  157. Muntané G, Janué A, Fernandez N, Odena MA, Oliveira E, Boluda S, Portero-Otin M, Naudí A, Boada J, Pamplona R, Ferrer I (2010) Modification of brain lipids but not phenotype in alpha-synucleinopathy transgenic mice by long-term dietary n-3 fatty acids. Neurochem Int 12 Nov 2009 [Epub ahead of print]Google Scholar
  158. Murck H, Manku M (2007) Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull 72:159–164PubMedCrossRefGoogle Scholar
  159. Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63:71–124PubMedCrossRefGoogle Scholar
  160. Mutez E, Duhamel A, Defebvre L, Bordet R, Destée A, Kreisler A (2009) Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson’s disease. Pharmacol Res 60:41–45PubMedCrossRefGoogle Scholar
  161. Nakamura T, Lipton SA (2007) S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding. Cell Death Differ 14:1305–1314PubMedCrossRefGoogle Scholar
  162. Nguyen T, Hamby A, Massa SM (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 102:11840–11845PubMedCrossRefGoogle Scholar
  163. Nitschke C, Fiechsig E, van den Brandt J, Lindner N, Luhrs T, Dittmer U, Klein MA (2007) Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie. Vet Microbiol 123:367–376PubMedCrossRefGoogle Scholar
  164. Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer’s disease. Rev Neurol (Paris) 155(Suppl 4):S53–S63Google Scholar
  165. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G (2007) Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 6:411–423PubMedCrossRefGoogle Scholar
  166. Origlia N, Arancio O, Domenici L, Yan SS (2009) MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother 9:1635–1645PubMedCrossRefGoogle Scholar
  167. Ozdinler PH, Macklis JD (2006) IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 9:1371–1381PubMedCrossRefGoogle Scholar
  168. Papadia S, Soriano FX, Léveillé F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, Yankner BA, Wyllie DJ, Ikonomidou C, Hardingham GE (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476–487PubMedCrossRefGoogle Scholar
  169. Park S, Kim HT, Yun S, Kim IS, Lee J, Lee IS, Park KI (2009) Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp Mol Med 41:487–500PubMedCrossRefGoogle Scholar
  170. Parsons RB, Price GC, Farrant JK, Subramaniam D, Adeagbo-Sheikh J, Austen BM (2006) Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms. Biochem J 399:205–214PubMedCrossRefGoogle Scholar
  171. Patel NK, Gill SS (2007) GDNF delivery for Parkinson’s disease. Acta Neurochir Suppl 97:135–154PubMedCrossRefGoogle Scholar
  172. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2:e18PubMedCrossRefGoogle Scholar
  173. Pelleymounter MA, Cullen MJ, Baker MB, Gollub M, Wellman C (1996) The effects of intrahippocampal BDNF and NGF on spatial learning in aged Long Evans rats. Mol Chem Neuropathol 29:211–226PubMedCrossRefGoogle Scholar
  174. Peng Y, Lee DY, Jiang L, Ma Z, Schachter SC, Lemere CA (2007) Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. Neuroscience 150:386–395PubMedCrossRefGoogle Scholar
  175. Perry G, Smith MA (2000) Promise and pitfalls of therapeutic to modify oxidant balance in chronic diseases. IDrugs 3:371–372PubMedGoogle Scholar
  176. Peterson AL, Nutt JG (2008) Treatment of Parkinson’s disease with trophic factors. Neurotherapeutics 5:270–280PubMedCrossRefGoogle Scholar
  177. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98:1141–1148PubMedCrossRefGoogle Scholar
  178. Planells-Cases R, Lerma J, Ferrer-Montiel A (2006) Pharmacological intervention at ionotropic glutamate receptor complexes. Curr Pharm Des 12:3583–3596PubMedCrossRefGoogle Scholar
  179. Postina R (2008) A closer look at alpha-secretase. Curr Alzheimer Res 5:179–186PubMedCrossRefGoogle Scholar
  180. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368PubMedCrossRefGoogle Scholar
  181. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, Jeon NL, Cotman CW (2009) Beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging 18 Jun 2009 [Epub ahead of print]Google Scholar
  182. Priller C, Dewachter I, Vassallo N, Paluch S, Pace C, Kretzschmar HA, van Leuven F, Herms J (2007) Mutant Clioquinol 1 alters synaptic transmission in cultured hippocampal neurons. J Biol Chem 282:1119–1127PubMedCrossRefGoogle Scholar
  183. Puri BK (2005) Treatment of Huntington’s disease with eicosapentaenoic acid. In: Yehuda S, Mostofsky DI (eds) Nutrients, stress and medical disorders. Nutrition and health (Series). Humana Press Inc, Totowa, NJ, pp 279–286Google Scholar
  184. Qiu C, Kivipetto M, von Strauss E (2009) Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111–128PubMedGoogle Scholar
  185. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ (2008) Br J Pharmacol 154:226–233PubMedCrossRefGoogle Scholar
  186. Rahman I, MacNee W (2000) Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 28:1405–1420PubMedCrossRefGoogle Scholar
  187. Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson’s disease. Prog Brain Res 175:201–216PubMedCrossRefGoogle Scholar
  188. Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306:81–84PubMedCrossRefGoogle Scholar
  189. Ray B, Banerjee PK, Geig NH, Lahiri DK (2009) Memantine treatment decreases levels of secreted Alzheimer’s amyloid precursor protein (APP) and amyloid beta (Abeta) peptide in the human neuroblastoma cells. Neurosci Lett [Epub ahead of print]Google Scholar
  190. Reddy PH (2008) Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med 10:291–315PubMedCrossRefGoogle Scholar
  191. Reddy PH, Mao P, Manczak M (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev 61:33–48PubMedCrossRefGoogle Scholar
  192. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341PubMedCrossRefGoogle Scholar
  193. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER (2006) Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimer Dis 10:399–406Google Scholar
  194. Ridha BH, Josephs KA, Rosser MN (2005) Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 65:481–482PubMedCrossRefGoogle Scholar
  195. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND (2006) Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 55:928–934PubMedCrossRefGoogle Scholar
  196. Robson LG, Dyalls S, Sidloff D, Michael-Titus AT (2008) Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol Aging 10 Jly [Epub a head print]Google Scholar
  197. Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 9:275–308PubMedCrossRefGoogle Scholar
  198. Romrell J, Fernandez HH, Okun MS (2003) Rationale for current therapies in Parkinson’s disease. Exp Opin Pharmacother 4:1747–1761CrossRefGoogle Scholar
  199. Sakaguchi S (2009) Systematic review of the therapeutics for prion diseases. Brain Nerve 61:929–938PubMedGoogle Scholar
  200. Sakowski SA, Schuyler AD, Feldman EL (2009) Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyyotroph Lateral Scler 10:63–73CrossRefGoogle Scholar
  201. Samadi P, Grégoire L, Rouillard C, Bédard PJ, Di Paolo T, Lévesque D (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 59:282–288PubMedCrossRefGoogle Scholar
  202. Sanchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373–379PubMedCrossRefGoogle Scholar
  203. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O‘Kane CJ, Schreiber SL, Rubinsztein DC (2007) Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat Chem Biol 3:331–338PubMedCrossRefGoogle Scholar
  204. Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet 17:170–178PubMedCrossRefGoogle Scholar
  205. Sastre M, Dewachter I, Rossner S (2006a) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103:443–448PubMedCrossRefGoogle Scholar
  206. Sastre M, Klockgether T, Heneka MT (2006b) Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci 24:167–176PubMedCrossRefGoogle Scholar
  207. Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171–82Q mouse models of Huntington’s disease. Neurobiol Dis 24:455–465PubMedCrossRefGoogle Scholar
  208. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol 63:1545–1550PubMedCrossRefGoogle Scholar
  209. Schmitt FA, van Dyck CH, Wichems CH, Olin JT For the Memantine MEM-MD-02 Study Group (2006) Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 20:255–262PubMedCrossRefGoogle Scholar
  210. Schmitt F, Ryan M, Cooper G (2007) A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease. Expert Opin Drug Metab Toxicol 3:135–141PubMedCrossRefGoogle Scholar
  211. Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, Bezard E (2008) The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson’s disease. J Neurosci 28:4311–4316PubMedCrossRefGoogle Scholar
  212. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMedGoogle Scholar
  213. Serhan CN (2005) Novel ω-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105:7–21PubMedCrossRefGoogle Scholar
  214. Sezeto HH (2006) Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8:E521–E531CrossRefGoogle Scholar
  215. Sharma S, Prasanthi RPJ, Schommer E, Feist G, Ghribi O (2008) Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis 32(3):426–432PubMedCrossRefGoogle Scholar
  216. Shen WH, Zhang CY, Zhang GY (2003) Antioxidants attenuate reperfusion injury after global brain ischemia through inhibiting nuclear factor-kappa B activity in rats. Acta Pharmacol Sin 24:1125–1130PubMedGoogle Scholar
  217. Siman R, Salidas S (2004) γ-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain. Neuroscience 129:615–628PubMedCrossRefGoogle Scholar
  218. Singh P, Suman S, Chandna S, Das TK (2009) Possible role of amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of Alzheimer’s disease. Bioinformation 3:440–445PubMedCrossRefGoogle Scholar
  219. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease mice. Biochim Biophys Acta 1762:616–626PubMedCrossRefGoogle Scholar
  220. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A (2008) Adherence to Mediterranean diet and health status: meta-analysis. Br Med J 337:a1334Google Scholar
  221. Song SM, Rauw G, Baker GB, Kar S (2008) Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 28:1989–2002PubMedCrossRefGoogle Scholar
  222. Sonkusare SK, Kaul CL, Ramarao P (2005) Dementia of Alzheimer’s disease and other neurodegenerative disorders–memantine, a new hope. Pharmacol Res 51:1–17PubMedCrossRefGoogle Scholar
  223. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2:343–353PubMedCrossRefGoogle Scholar
  224. Spires TL, Hannan A (2005) Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FASEB J 272:2347–2361Google Scholar
  225. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ (2006) Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease mice. Biochim Biophys Acta 1762:373–380PubMedCrossRefGoogle Scholar
  226. Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, Beyreuther K, Masters CL, Collins SJ, Cappai R (2001) Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106–126. J Neurosci Res 65:565–572PubMedCrossRefGoogle Scholar
  227. Sullivan PG, Rabchevsky AG, Waldmeier PC, Spiringer JE (2005) J. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? Neurosci Res 79:231–239CrossRefGoogle Scholar
  228. Tan DX, Manchester LC, Sainz R, Mayo JC, Alvares FL, Reiter RJ (2003) Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin Ther Patents 13:1513–1543CrossRefGoogle Scholar
  229. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148–154PubMedCrossRefGoogle Scholar
  230. Tarawneh R, Holtzman DM (2009) Critical issues for successful immunotherapy in Alzheimer’s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 8:144–159PubMedCrossRefGoogle Scholar
  231. Todd NV, Morrow J, Doh-Ura K, Dealler S, O’Hare S, Farling P, Duddy M, Rainov NG (2005) Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 50:394–396PubMedCrossRefGoogle Scholar
  232. Tomita T (2009) Alzheimer’s disease treatment by inhibition/modulation of the gamma-secretase activity. Rinsho Shinkeigaku 49:845–847PubMedCrossRefGoogle Scholar
  233. Townsend L, Ongini E, Wenk G (2004) Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:1592–1601CrossRefGoogle Scholar
  234. Trejo JL, Carro E, Nunez A, Torres-Aleman I (2002) Sedentary life impairs self-reparative processes in the brain: the role of serum insulin-like growth factor-I. Rev Neurosci 13:365–374PubMedGoogle Scholar
  235. Tsuboi Y, Doh-ura K, Yamada T (2009) Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 29(5):632–636PubMedCrossRefGoogle Scholar
  236. Tsujimoto Y, Shimizu S (2003) Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12:835–840CrossRefGoogle Scholar
  237. Turnbull S, Tabner BJ, Brown DR, Allsop D (2003) Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106–126. NeuroReport 14:1743–1745PubMedCrossRefGoogle Scholar
  238. Urosevic N, Martin RN (2008) Infection and Alzheimer’s disease: the APOE epsilon4 connection and lipid metabolism. J Alzheimer Dis 13:421–435Google Scholar
  239. Urushitani M (2009) Future perspectives of immunotherapy against ALS. Rinsho Shinkeigaku 49:818–820PubMedCrossRefGoogle Scholar
  240. Valverde G, De Andrade D, Madureira de Oliveria D, Barreto G, Bertolino LA, Saraceno E, Capani F, Giraldez LD (2008) Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells. Brain Res 1198:188–196CrossRefGoogle Scholar
  241. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al (1999) β-Secretase cleavage of Alzheimer’s amyloid precursor protein by transmembrane aspartic protease BACE. Science 286:735–741PubMedCrossRefGoogle Scholar
  242. Vaughan CJ (2003) Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 91:23B–29BPubMedCrossRefGoogle Scholar
  243. Vaynman S, Ying Z, Gomez-Pinilla F (2004) Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci 20:2580–2590PubMedCrossRefGoogle Scholar
  244. Vaynman S, Gomez-Pinilla F (2006) Revenge of the “sit”: how lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity. J Neurosci Res 84:699–715PubMedCrossRefGoogle Scholar
  245. Vaynman S, Ying Z, Wu A, Gomez-Pinilla F (2006) Coupling energy metabolism with a mechanism to support brain-derived neurotrophic factor-mediated synaptic plasticity. Neuroscience 139:1221–1234PubMedCrossRefGoogle Scholar
  246. Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, Zahn R (2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 46:3563–3564PubMedCrossRefGoogle Scholar
  247. Vulih-Shutzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I (2007) Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323:438–449CrossRefGoogle Scholar
  248. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ (2003) Cyclophilin D as a drug target. Curr Med Chem 10:1485–1506PubMedCrossRefGoogle Scholar
  249. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington’s disease. Proc Natl Acad Sci USA 100:10483–10487PubMedCrossRefGoogle Scholar
  250. Wang R, Tang XC (2005) Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals 14:71–82PubMedCrossRefGoogle Scholar
  251. Wang R, Zhang D (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22:2376–2380PubMedCrossRefGoogle Scholar
  252. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC (2006) Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharmaceut Des 12:3521–3533CrossRefGoogle Scholar
  253. Wang J, Zhang HY, Tang XC (2010) Huperzine A improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88:807–815PubMedGoogle Scholar
  254. Wenk GL, Parsons CG, Danysz W (2006) Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17:411–424PubMedCrossRefGoogle Scholar
  255. White AR, Hawke SH (2003) Immunotherapy as a therapeutic treatment for neurodegenerative disorders. J Neurochem 87:801–808PubMedCrossRefGoogle Scholar
  256. Wilczak N, de Keyser J (2005) Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocr Dev 9:160–169PubMedCrossRefGoogle Scholar
  257. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314:664–666PubMedCrossRefGoogle Scholar
  258. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O‘Kane CJ, Floto RA, Rubinsztein DC (2008) Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nat Chem Biol 4:295–305PubMedCrossRefGoogle Scholar
  259. Wolozin B (2002) Cholesterol and Alzheimer’s disease. Biochem Soc Trans 30:525–529PubMedCrossRefGoogle Scholar
  260. Wong HK, Bauer PO, Kurosawa M, Goswami A, Washizu C, Machida Y, Tosaki A, Yamada M, Knöpfel T, Nakamura T, Nukina N (2008) Blocking acidsensing ion channel 1 alleviates Huntington’s disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 17:3223–3235PubMedCrossRefGoogle Scholar
  261. Wu TY, Chen CP (2009) Dual action of memantine in Alzheimer disease: a hypothesis. Taiwan J Obstet Gynecol 48:273–277PubMedCrossRefGoogle Scholar
  262. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB (2009) Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 34:2344–2357PubMedCrossRefGoogle Scholar
  263. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101:57–66PubMedCrossRefGoogle Scholar
  264. Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173–183PubMedCrossRefGoogle Scholar
  265. Zhou J, Tang XC (2002) Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett 526:21–25PubMedCrossRefGoogle Scholar
  266. Zhou J, Yi J, Fu R, Liu E, Siddique T, Ríos E, Deng HX (2010) Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J Biol Chem 285:705–712PubMedCrossRefGoogle Scholar
  267. Zimmermann M, Gardoni F, Di Luca M (2005) Molecular rationale for the pharmacological treatment of Alzheimer’s disease. Drugs Aging 22(Suppl 1):27–37PubMedCrossRefGoogle Scholar
  268. Zona C, Siniscalchi A, Mercuri NB, Bernardi G (1998) Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85:931–938PubMedCrossRefGoogle Scholar
  269. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24:8853–8861PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Molecular and Cellular BiochemistryThe Ohio State UniversityColumbusUSA

Personalised recommendations